Ultrasound to Enhance Paclitaxel Uptake in Critical Limb Ischemia: the PACUS Trial

NACompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2015

Conditions
Peripheral Arterial Disease, Angioplasty
Interventions
DEVICE

Local exposition of target lesion to high intensity, low-frequency ultrasound

Target lesion was exposed to 60 seconds of high intensity, low-frequency ultrasound generated by the Genesis™ system ( CardioProlific Inc., Hayward, CA). The ultrasound catheter is removed after the exposition.

DEVICE

drug eluting ballon angioplasty

Target lesion was treated with an angioplasty, performed using the INPACT Admiral drug eluting ballon (Medtronic)

DEVICE

Flow occlusion with an angioplasty balloon

Inflation of a 2 cm long balloon catheter Admiral (Medtronic) , located distally to the treatment area, in order to obtain a flow cessation

DRUG

Local Paclitaxel infusion

Paclitaxel in a mixture with contrast medium at 1.0 µg/mm³ concentration was delivered to the treatment area for 60 seconds. The column of the Paclitaxel mixture filling the vessel was observed under the fluoroscopy and sustained during 60 seconds. The Paclitaxel /contrast medium mixture was then aspired with a 50 cc syringe and the distal balloon was deflated.

PROCEDURE

Angiographic control

A final angiographic control was performed with injection of 10 cc of contrast medium and compared with the pre-procedural one.

All Listed Sponsors
lead

University of Rome Tor Vergata

OTHER

NCT02625740 - Ultrasound to Enhance Paclitaxel Uptake in Critical Limb Ischemia: the PACUS Trial | Biotech Hunter | Biotech Hunter